Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Affilogic has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, yet they are contained within only 2 distinct art units. This structure indicates that while the company is interacting with multiple examiners, the technical subject matter is concentrated in a small number of art units, potentially leading to some consistency in the prior art cited across the pending office actions.
LEE, JIA-HAI is the busiest examiner for the portfolio, with 1 pending office action. Because there are multiple examiners for the pending office actions, the workload is perfectly distributed among the assigned staff. This lack of concentration under any single individual means that the prosecution strategy must account for the varied perspectives of several people. The focus within 2 distinct art units remains the primary point of organizational consistency for these filings, which may streamline the handling of related technical arguments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 1 | 49.0% | +47.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282613 | ANTI-FACTOR C3 SAC7D VARIANTS AND THEIR MEDICAL USE FOR TREATING COMPLEMENT-MEDIATED DISORDERS | LEE, JIA-HAI | — |
| 18277126 | COMPOUNDS AND METHODS FOR EXTENDING HALF LIFE OF BIOMOLECULES | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17906000 | VARIANTS OF SAC7D AND THEIR USE IN CANCER THERAPY | ALSOMAIRY, SARAH ABDOALATIF | — |
| 17283369 | BINDERS FOR INHIBITING FORMATION OF MULTIMERIC PROTEINS | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1658 | 3 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18282613 | ANTI-FACTOR C3 SAC7D VARIANTS AND THEIR MEDICAL USE FOR TREATING COMPLEMENT-MEDIATED DISORDERS | LEE, JIA-HAI | 1658 | §103DP | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18277126 | COMPOUNDS AND METHODS FOR EXTENDING HALF LIFE OF BIOMOLECULES | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §112DP | Non-Final OA | — | Pending | Aug 14, 2023 |
| 17906000 | VARIANTS OF SAC7D AND THEIR USE IN CANCER THERAPY | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §112 | Final Rejection | — | Pending | Sep 09, 2022 |
| 17283369 | BINDERS FOR INHIBITING FORMATION OF MULTIMERIC PROTEINS | NIEBAUER, RONALD T | 1658 | §103§112DP | Non-Final OA | — | Pending | Apr 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial